Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Rotolo

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Oncology|June 30, 2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trialMartine Bagot, Pierluigi Porcu, Anne Marie-Cardine, et al.
Journal of Hematology & Oncology|February 25, 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trialRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2018
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung CancerSiddhartha Devarakonda, Federico Rotolo, Ming-Sound Tsao, et al.
Cancer|October 5, 2020
Predictive classifier for intensive treatment of head and neck cancerKaveh Zakeri, Federico Rotolo, Benjamin Lacas, et al.
Critical Care Medicine|October 11, 2022
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])Julien Carvelli, Ferhat Meziani, Jean Dellamonica, et al.
Journal of the National Cancer Institute|December 9, 2016
Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysisFederico Rotolo, Jean-Pierre Pignon, Jean Bourhis, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Oncology|June 30, 2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trialMartine Bagot, Pierluigi Porcu, Anne Marie-Cardine, et al.
Journal of Hematology & Oncology|February 25, 2021
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trialRobert J Kreitman, Claire Dearden, Pier Luigi Zinzani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2018
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung CancerSiddhartha Devarakonda, Federico Rotolo, Ming-Sound Tsao, et al.
Cancer|October 5, 2020
Predictive classifier for intensive treatment of head and neck cancerKaveh Zakeri, Federico Rotolo, Benjamin Lacas, et al.
Critical Care Medicine|October 11, 2022
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])Julien Carvelli, Ferhat Meziani, Jean Dellamonica, et al.
Journal of the National Cancer Institute|December 9, 2016
Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysisFederico Rotolo, Jean-Pierre Pignon, Jean Bourhis, et al.
Pageof 3